Cognition Therapeutics closed at $0.64 on Nov 5, down 6.26%, 64.4% below its 52-week closing high. Volume of 553.6K shares was 0.89× its 20-day average (close to normal).
Split-adjusted performance: -31.6% over one month, -44.8% over six months, -59.2% over one year.
Short interest was 7.0M shares at the Oct 15 settlement, down 7.1% from the prior report (8.3% of float, 9.9 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CGTXCognition Therapeutics | $0.6405 | −6.26% | −44.8% | — | — | — | $60.9M | |
| CRDFCardiff Oncology | $0.7602 | −12.51% | −52.5% | −14.0% | −8882.7% | — | $59.1M | Compare |
| CSBRChampions Oncology | $4.79 | −0.83% | −20.0% | +8.8% | −2.8% | — | $66.7M | Compare |
| INKTMiNK Therapeutics | $10.10 | −4.70% | −9.7% | — | — | — | $51.6M | Compare |
| ELOXEloxx Pharmaceuticals | $12.59 | −1.18% | — | — | — | — | $50.8M | Compare |
| KLRSKalaris Therapeutics | $2.10 | +3.96% | −59.2% | — | — | — | $50.0M | Compare |
| GRMLGreenland Mines | $3.62 | −7.42% | — | — | — | — | $49.5M | Compare |
| TNYATenaya Therapeutics | $0.3400 | −8.08% | −59.9% | — | −3909.3% | — | $77.5M | Compare |
| TILInstil Bio | $6.97 | −0.29% | −13.2% | — | — | — | $47.3M | Compare |
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
